Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

Krajewski, Katherine M.; Braschi‐Amirfarzan, Marta; DiPiro, Pamela J.; Jagannathan, Jyothi P.; Shinagare, Atul B.

doi:10.3348/kjr.2017.18.1.28

Cited by 26 publications

(18 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first of these is blocking proliferation through the use of small molecule tyrosine kinase inhibitors (TKi) which causes impeding the activation of the signalling pathway by blocking the action of an abnormal protein (Tab. 1) [1,2].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

“…Drug resistance can be one of the most significant limiting factors during anti-cancer treatment. The resistance may result from the adaptation of tumour cells caused by regular drug application or from the presence of pre-existing changes at the molecular level [30,2]. Congenital cellular resistance is characterized by a lack of response to drugs from the beginning of their use.…”

Section: Anti-cancer Drug Resistancementioning

confidence: 99%

“…rapidly expanding knowledge of molecular biology and cancer genetics has provided us with tools that make personalized medicine possible. Molecularly targeted therapy focuses on the identification of molecular changes on the level of a single patient, and also on optimization and individualization of treatment, as well as individual characteristics of the tumour microenvironment [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

“…each cell has specific cell-surface receptors, which are responsible for activation of a response to extracellular stimuli. Often these proteins are used as the target of therapy because they show a relatively high frequency of mutation or overexpression [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Limitations of molecularly targeted therapy

Balik

Modrakowska

Maj

et al. 2019

Medical Research Journal

View full text Add to dashboard Cite

Personalized medicine is an extension of traditional medicine is based on a highly individual approach to each patient. One of the most important tools that allow this approach is targeted therapy. It focuses mainly on blocking cancer cell's proliferation and angiogenesis capabilities by interfacing with specific molecules that are involved in the growth and progression of the tumour. Small-molecule inhibitors and monoclonal antibodies are the main drugs that are currently in use in order to affect the specific biochemical pathways in cancer cells. However, likewise any other cancer therapies, targeted therapy has its own limitations. For instance, identifying a molecular target needed to begin treatment is one of those hardships. A specific molecule is crucial in this way of treatment. The other limitation is the toxicity that appears during the treatment, the same as in the case of traditional chemotherapy and radiotherapy. Furthermore, the cost of this therapy is significantly higher compared to classical treatments. However, the main obstacles are mechanisms of cancer drug resistance which are often developing in response to given drugs. In many cases, it makes further treatment impossible. This article is focusing on the limitations of molecularly targeted therapy.

show abstract

Section: Mechanism Of Actionmentioning

confidence: 99%

Section: Anti-cancer Drug Resistancementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Limitations of molecularly targeted therapy

Balik

Modrakowska

Maj

et al. 2019

Medical Research Journal

View full text Add to dashboard Cite

show abstract

“…Различают 2 изоформы VEGF-A, диаметрально отличающиеся друг от друга по влиянию на ангиогенез: проангиогенные свойства характерны только для изоформ типа a, в то время как b-изофор-мы проявляют антиангиогенный эффект. Кроме VEGF-A, в организме человека присутствуют еще 4 вида VEGF (-B, -C, -D, -E), кодируемые разными генами и отличающи-еся выполняемыми функциями [26].…”

Section: основные клеточные сигнальные пути вовлеченные в патогенез unclassified

Molecular Basis of Modern Targeted Therapy for Squamous Cell Carcinoma of the Tongue and Oral Mucosa With Monoclonal Antibodies

Льянова¹,

Владимирова²,

Франциянц³

et al. 2017

Zlokač. opuholi

View full text Add to dashboard Cite

Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?

Beaumont¹,

Faye²,

Iannessi

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Objective: We compared therapeutic response of Varlitinib + Capecitabine (VC) versus Lapatinib + Capecitabine (LC) in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab therapy by assessing changes in target lesion (TL) diameter and volume per location.Methods: We retrospectively analyzed the CT data of the ASLAN001-003 study (NCT02338245). We analyzed TL size and number at each location focusing on therapeutic response from baseline to Week 12. We used TL diameter and volume to conduct an inter-arm comparison of the response according to: RECIST 1.1; strati ed per TL location and; considering TLs independently. Multiple pairwise intra-arm comparisons of therapeutic responses were performed. Considering TL independently, weighted models were designed by adding weighted mean TL responses grouped by location. A sensitivity analysis tested the robustness of results.Results: We evaluated 42 patients (88 TL) and 35 patients (74 TL) respectively at baseline and Week 12.We found reductions in breast TL burden in the VC arm compared to the LC arm (p=0.002 (diameter), p<0.001 (volume)). Responses and TL sizes at baseline were not correlated.Explained variabilities of volume change per TL location, patient and patient:TL interaction were 36%, 10% and 4% (VC), and 13%, 1% and 23%, (LC).A test of inter-arm difference of responses yielded p=0.07 (diameter), and p<0.001 (volume).The sensitivity analysis con rmed our ndings.Conclusions: The therapeutic responses differed across locations; differential responses were drug-dependent. Strati ed analysis provides better drug comparisons and is a powerful tool to understand TL heterogeneity.

show abstract

Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

Cited by 26 publications

References 93 publications

Limitations of molecularly targeted therapy

Limitations of molecularly targeted therapy

Molecular Basis of Modern Targeted Therapy for Squamous Cell Carcinoma of the Tongue and Oral Mucosa With Monoclonal Antibodies

Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?

Contact Info

Product

Resources

About